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Abstract
Whether antiplatelet therapy is associated with better outcomes among patients with infective endocarditis (IE) remains controversial.
A retrospective study was conducted concerning all patients with IE, treated in a tertiary-care centre of Canada between 1991 and 2006,
who satisﬁed the modiﬁed Duke criteria for a deﬁnite or possible IE. The primary outcome was all-cause mortality within 90 days of diagno-
sis. A secondary outcome was the development of major systemic embolism. In total, 241 patients satisﬁed the inclusion criteria, 75 of
whom had been on chronic antiplatelet therapy prior to developing endocarditis. Seventy-one (29.5%) patients died. According to multivari-
ate analysis, age, a high Charlson score, aortic valve involvement, myocardial infarction and presence of a perivalvular abscess were strongly
associated with mortality. Undergoing valvular replacement (adjusted OR (AOR) 0.28, 95% CI 0.09–0.84) and chronic antiplatelet therapy
before IE (AOR 0.27, 95% CI 0.11–0.64) correlated with lower mortality. There was a trend for lower mortality among patients started
on antiplatelet drugs after admission (AOR 0.29, 95% CI 0.08–1.13). The effect of aspirin on mortality was much the same in patients who
received 325 or 80 mg daily. Chronic antiplatelet therapy was not associated with a signiﬁcantly lower risk of major embolism. In conclu-
sion, chronic antiplatelet therapy was associated with lower mortality among patients with IE, independently of any effect on major embo-
lism. Whether or not a beneﬁcial effect could be replicated by initiating antiplatelet therapy at the time of diagnosis remains unproven.
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Introduction
The annual incidence of infective endocarditis (IE) has
remained stable over the past 25 years [1–4]. However, age
at onset has increased and the peak incidence is now seen
among individuals aged 70–80 years [5]. Staphylococcus aureus
has become the leading cause of IE in many countries, and
methicillin-resistant S. aureus has emerged as an aetiological
agent [6]. The case-fatality ratio of IE remains high, and was
between 17% and 27% in recent series [6–8]. Therapy has
changed little, apart from the increasing use of vancomycin
for methicillin-resistant S. aureus endocarditis [9]. In addition
to antibiotics, surgical therapy can decrease mortality in
speciﬁc subgroups, i.e. in the presence of congestive heart
failure unresponsive to medical treatment, a damaged valve
with severe regurgitation, a causative organism resistant to
antibiotics, persistent infection, or recurrent embolisms [9].
One-third of patients with IE develop systemic embolism,
a potentially devastating complication [1,7,10–12]. To date,
antibiotic therapy is the only measure that is effective in pre-
venting embolism [13,14]. Experimental models have demon-
strated the efﬁcacy of antiplatelet drugs in reducing
vegetation size and bacterial titres within vegetations [15,16],
but a randomized trial failed to demonstrate a beneﬁt of
aspirin (325 mg daily), introduced shortly after diagnosis
[17]. Recently, a retrospective study showed that use of anti-
platelet drugs before the onset of IE was associated with a
lower risk of embolism [18]. To better delineate the poten-
tial utility of antiplatelet therapy in IE and its impact, not only
on embolism but also on mortality, a retrospective cohort
study of all cases of IE treated in a single tertiary-care hospi-
tal of Canada over a 16-year period was carried out.
Materials and Methods
This retrospective observational study was performed
at the Centre Hospitalier Universitaire de Sherbrooke, a
university hospital with cardiac surgery facilities, in the
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province of Quebec, Canada. Through the hospital
database of discharge diagnoses, all adult patients admitted
from January 1991 to December 2006 with IE as their
principal or secondary diagnosis were identiﬁed. Patients
were included if endocarditis was deemed to be infectious
and if they retrospectively met the modiﬁed Duke criteria
for a deﬁnite or possible IE [19]. From the medical
records, demographic information, data on pre-existing
comorbidities included in the Charlson score [20], risk fac-
tors for IE (prosthetic valve, other cardiac abnormality,
infection at another site, invasive procedure, use of injec-
tion drugs), pathogens, clinical, laboratory and echocardio-
graphic ﬁndings, treatment (medical, surgical), chronic
antiplatelet therapy, cardiac and extracardiac complications
and mortality were extracted.
Immunosuppression was deﬁned as one or more of the
following: human immunodeﬁciency virus infection, leukae-
mia, lymphoma, neutropenia, organ transplant, and long-term
use of corticosteroids or other immunosuppressants.
Chronic antiplatelet therapy was deﬁned as use of aspirin or
clopidogrel for ‡6 months prior to admission. Major embo-
lism was deﬁned as one or more of coronary, splenic, renal,
or mesenteric embolism, ischaemic stroke or peripheral
embolism.
Data were analysed with STATA 8.0 software (Stata-
CorpLP, College Station, TX, USA). Proportions were com-
pared with the chi-square test or, when numbers
were small, Fisher’s exact test. ORs and their 95% CIs were
calculated. The primary outcome was all-cause mortality
occurring within 90 days of diagnosis of IE. In the study
institution, mortality occurring outside the hospital is
recorded via the provincial registry of deaths. Secondary
outcomes included the development of systemic embolism
or of haemorrhagic strokes. Unconditional logistic regres-
sion was used for multivariate analysis. Models were built up
sequentially, starting with the variable most strongly associ-
ated with the outcome and continuing until no other vari-
able reached signiﬁcance. Only variables associated with the
outcome in univariate analyses (p <0.05) or those that were
a priori of major interest (antiplatelets, bacterial aetiology)
were tested. When the ﬁnal model was reached, each vari-
able was dropped in turn to assess its effect. Different mod-
els were compared using the likelihood ratio test, keeping in
the ﬁnal model variables signiﬁcant at the p = 0.05 level.
Results
In total, 241 patients satisﬁed the inclusion criteria (163 deﬁ-
nite and 78 possible IE). Their age varied between 20 and
94 years (median, 65 years; interquartile range, 50–76 years).
The Charlson scores varied between 0 and 12 (median, 3,
interquartile range, 1–5). Almost half (118, 49%) of the
episodes were caused by S. aureus. Seventy-ﬁve patients
(31%) were on chronic antiplatelet therapy: 67 were
receiving aspirin alone, ﬁve a combination of aspirin and
clopidogrel, and three clopidogrel alone. Antiplatelet agents
were continued after the diagnosis of IE in 65 of these 75
patients. In a further 23 patients (10%), treatment with anti-
platelet agents was initiated during the hospitalization.
Table 1 shows some selected characteristics of patients
who had or had not been receiving chronic antiplatelet ther-
apy immediately prior to diagnosis of IE. Patients on chronic
antiplatelet therapy were older and had a higher Charlson
score than those not receiving such therapy. The speciﬁc dis-
eases associated with chronic antiplatelet therapy corre-
sponded to established indications, or medical conditions
associated with these indications. The two groups did not
differ with respect to aetiological agent, frequency of valve
replacement or size of the largest vegetation.
Table 2 shows risk factors for all-cause mortality occur-
ring within 90 days of diagnosis. Seventy-one patients
(29.5%) died within 90 days. Age and a high Charlson score
were associated with higher mortality. Some risk factors that
predisposed patients to develop endocarditis (mitral valve
prolapse, pacemaker or deﬁbrillator, past endocarditis) were
not associated with mortality once they did have IE (data not
shown). However, injection drug use was associated with
lower mortality (0/16 patients with right-sided IE and 71/225
(32%) with left-sided IE died, p = 0.004). Patients with
S. aureus IE tended to have higher mortality. Developing a
myocardial infarction as a complication of IE was, predictably,
associated with higher mortality, whereas undergoing valve
replacement correlated with lower mortality. There was
much confounding between variables, as can be inferred from
Table 1. The effect of chronic antiplatelet therapy on mortal-
ity was strongly confounded by age and Charlson score. The
effect of valvular replacement on mortality was confounded
by age and Charlson score (towards the null value) but even
more strongly by aortic valve involvement and perivalvular
abscess (which had the opposite effect). According to multi-
variate analysis, age, a high Charlson score, aortic valve
involvement, myocardial infarction and presence of a perival-
vular abscess were strongly associated with mortality.
Undergoing valvular replacement (adjusted OR (AOR) 0.28,
95% CI 0.09–0.84) and being on chronic antiplatelet therapy
before IE (AOR 0.27, 95% CI 0.11–0.64) correlated with a
lower mortality. The effect of aspirin on mortality was very
much the same in patients who had received 325 mg daily
(AOR 0.25; 95% CI 0.08–0.76) and those who had received
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80 mg daily (AOR 0.23, 95% CI 0.07–0.70). When added
to the preceding model, S. aureus aetiology tended to be
associated with higher mortality (AOR 1.99, 95% CI 0.98–
4.00, p = 0.055). The effect of chronic antiplatelet therapy
on mortality appeared to be more pronounced in patients
infected with pathogens other than S. aureus (AOR 0.11,
95% CI 0.02–0.49) than among patients with S. aureus IE
(AOR 0.46, 95% CI 0.14–1.55), but there was no signiﬁcant
interaction (p = 0.09). No interaction was found between
S. aureus aetiology and any of the other independent corre-
lates or mortality, or between use of antiplatelet agents and
other variables.
Table 3 shows risk factors for major embolism among
patients with left-sided endocarditis. Risk factors that predis-
posed patients to IE were not associated with embolism
(data not shown). In multivariate analysis, older age was
associated with a lower risk of major embolism, whereas
vegetation size, de novo congestive heart failure and heart
block were associated with a higher risk. When ﬁtted into
this model, chronic antiplatelet therapy was not associated
with a signiﬁcantly lower risk of embolism (S. aureus, AOR
0.44, 95% CI 0.13–1.50, p = 0.19; other pathogens, AOR
0.70, 95% CI 0.23–2.13, p = 0.53; all, AOR 0.58, 95% CI
0.26–1.29, p = 0.18).
Haemorrhagic strokes were not more common among
patients undergoing chronic antiplatelet therapy (2/75 (3%)
vs. 10/166 (6%), p = 0.35). This risk increased among
patients who received warfarin prior to diagnosis of IE (6/56
(11%) vs. 6/185 (3%) among those not on warfarin,
p = 0.04).
Discussion
The main ﬁnding of this observational study is that, among
patients with IE, chronic administration of antiplatelet drugs
(essentially aspirin) prior to the development of endocarditis
was associated with lower mortality. Administration of anti-
platelet agents was more common among older patients and
those with various comorbidities, variables that are them-
selves strongly associated with mortality. Adjustment for
these and other confounding factors showed that patients
undergoing chronic antiplatelet therapy were less likely to
die than others. This protective effect of chronic antiplatelet
therapy occurred despite a lack of effect on embolism. The
question arises of how this can be reconciled with previously
published evidence.
Animal models have demonstrated the efﬁcacy of aspirin
in reducing weight and echocardiographically monitored
growth of vegetations, and bacterial titres within vegetations
and renal tissues, as well as in enhancing the sterilization of
vegetations [15,16,21].
Table 1. Characteristics of patients
receiving, or not receiving, chronic
antiplatelet therapy prior to diag-
nosis of endocarditis
No antiplatelet
therapy,
n = 166 (%)
Undergoing
antiplatelet
therapy,
n = 75 (%) p-Value
Age
Years (median) 60 74 <0.001
Interquartile range 46–73 63–80
Sex, no. (%)
Male 105 (63) 55 (73) NS
Female 61 (37) 20 (27)
Charlson score, no. (%)
0–1 68 (41) 14 (19)
2–4 59 (36) 30 (40) <0.001
‡5 39 (23) 31 (41)
Speciﬁc medical condition, no. (%)
Coronary heart disease 40 (24) 43 (57) <0.001
Congestive heart failure 24 (14) 21 (28) 0.02
Peripheral vascular disease 37 (22) 35 (47) <0.001
Cerebrovascular disease 19 (11) 20 (27) 0.004
Diabetes without complications 15 (9) 19 (25) 0.001
Diabetes with complications 11 (7) 17 (23) <0.001
Chronic renal failure 27 (16) 23 (31) 0.02
Prosthetic valve, no. (%) 38 (23) 20 (27) NS
Pathogen, no. (%)
Staphylococcus aureus 81 (49) 37 (49) NS
Other 85 (51) 38 (51)
Aortic valve involved, no. (%) 55 (33) 19 (25) NS
Mitral valve involved, no. (%) 60 (36) 25 (33) NS
Size of largest vegetation, no. (%)
No vegetation seen 85 (51) 41 (54)
<10 mm 36 (22) 14 (19) NS
‡10 mm 45 (27) 20 (27)
Valve replacement, no. (%) 35 (21) 11 (15) NS
NS, not signiﬁcant.
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Some of these effects are dose-dependent, and are lost at
higher dosages [15,21]. Adherence of S. aureus cells to sterile
vegetations, platelets, ﬁbrin matrices and ﬁbrin–platelet
matrices is reduced when they are pre-exposed to aspirin
[15]. Ticlopidine seems to have similar effects [22]. In
S. aureus, salicylic acid also attenuates virulence phenotypes
(e.g. a-haemolysin secretion and ﬁbrinogen and ﬁbronectin
binding) by downmodulating staphylococcal global regulons
and structural genes (hla, fnbA, sarA and agr) and by activating
the sigB operon [23–25]. Similar effects on virulence have
been reported for streptococci and Staphylococcus epidermidis
[26,27].
There is now some evidence that this may translate into
clinical effects. Patients haemodialysed via tunnelled catheters
Table 2. Risk factors for 90-day
mortality (all-cause) among all
patients with deﬁnitive or possible
endocarditis, according to univari-
ate and multivariate analyses
Death/
total (%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Age
Per additional year 1.05 (1.03–1.07)a 1.06 (1.04–1.09)a
Sex
Male 42/160 (26) 1.00 NS
Female 29/81 (36) 1.57 (0.84–2.91)
Charlson score
0–1 15/82 (18) 1.00 1.00
2–4 18/89 (20) 1.13 (0.53–2.43) 0.77 (0.31–1.92)
‡5 38/70 (54) 5.30 (2.55–11.02)a 5.06 (2.00–12.86)a
Prosthetic valve
No 54/183 (30) 1.00 NS
Yes 17/58 (29) 0.99 (0.52–1.89)
Intravenous drug user
No 70/222 (32) 1.00 NS
Yes 1/19 (5) 0.12 (0.02–0.92)b
Pathogen
Streptococci 10/51 (20) 1.00 NS
Staphylococcus aureus 41/118 (35) 2.18 (0.99–4.80)b
Coagulase-negative staphylococci 6/21 (29) 1.64 (0.51–5.30)
Enterococci 5/22 (23) 1.21 (0.36–4.06)
Other 6/17 (35) 2.24 (0.67–7.51)
Culture-negative 3/12 (25) 1.37 (0.31–5.99)
Aortic valve involved
No 46/167 (28) 1.00 1.00
Yes 25/74 (34) 1.34 (0.74–2.42) 2.89 (1.25–6.67)b
Mitral valve involved
No 47/156 (30) 1.00 NS
Yes 24/85 (28) 0.91 (0.51–1.63)
Congestive heart failure, de novo
No 51/190 (27) 1.00 NS
Yes 20/51 (39) 1.76 (0.92–3.36)
Perivalvular abscess
No 63/221 (29) 1.00 1.00
Yes 8/20 (40) 1.67 (0.65–4.28) 4.68 (1.34–16.38)b
Atrioventricular block, de novo
No 65/211 (31) 1.00 NS
Yes 6/30 (20) 0.56 (0.22–1.44)
Myocardial infarction
No 60/226 (27) 1.00 1.00
Yes 11/15 (73) 7.61 (2.33–24.81)a 10.79 (2.43–47.94)b
Ischaemic/haemorrhagic stroke
No 59/206 (29) 1.00 NS
Yes 12/35 (34) 1.30 (0.61–2.78)
Size of largest vegetation
No vegetation seen 43/126 (34) 1.00 NS
<10 mm 13/50 (26) 0.68 (0.33–1.41)
‡10 mm 15/65 (23) 0.58 (0.29–1.15)
Cerebral abscess
No 69/237 (29) 1.00 NS
Yes 2/4 (50) 2.43 (0.34–17.6)
Major embolism
No 51/166 (31) 1.00 NS
Yes 20/75 (27) 0.82 (0.45–1.51)
Glomerulonephritis
No 64/221 (29) 1.00 NS
Yes 7/20 (35) 1.32 (0.50–3.46)
Antiplatelet agents
None before, none after admission 43/143 (30) 1.00 1.00
None before, started after admission 7/23 (30) 1.02 (0.39–2.65) 0.29 (0.08–1.13)
Chronic therapy before admission 21/75 (28) 0.90 (0.49–1.68) 0.27 (0.11–0.64)b
Valve replacement
No 63/195 (32) 1.00 1.00
Yes 8/46 (17) 0.44 (0.19–1.00)b 0.28 (0.09–0.84)b
NS, not signiﬁcant.
ap £0.001.
bp <0.05.
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who received aspirin (325 mg daily) were half as likely than
others to develop S. aureus bacteraemia [28]. In a retrospec-
tive study of IE at the Mayo Clinic, patients receiving chronic
antiplatelet therapy were less likely than others to develop
embolism [18]. According to univariate analysis, mortality did
not differ between groups; as in our study, those on chronic
antiplatelet therapy were older and had a higher Charlson
score, but no multivariate analysis of risk factors for mortal-
ity was reported [18]. In contrast, in a randomized con-
trolled trial in which 115 IE patients were randomized with
respect to aspirin treatment (325 mg daily) or placebo, no
beneﬁcial effect was documented on embolism or in-hospital
mortality (6.7% in the aspirin group and 10.9% in the placebo
group) [17]. Bleeding tended to be more frequent (p 0.075)
in the aspirin group, but this reﬂected mostly differences in
the frequency of minor bleeding [17]. In a post hoc analysis,
the placebo group of the latter study was compared to
patients excluded because of chronic antiplatelet therapy,
and similar conclusions were reached [12]. This trial was not
powered to detect an impact on mortality; indeed, it
recruited only one-third of its targeted sample size, calcu-
lated on the basis of a potential 33% reduction in risk of
embolism [17].
The hypothesis was that, among study participants, the
beneﬁcial effect of aspirin on survival may have been mainly a
consequence of the drug-mediated attenuation of bacterial
virulence and more rapid sterilization of vegetations,
potentially leading to less severe valvular destruction or local
extension, rather than an effect on major embolism and the
attendant mortality.
There were limitations to this study. First, as in all observa-
tional studies, and although information concerning many
Table 3. Risk factors for major
embolism (one or more of: coro-
nary, splenic, renal or mesenteric
embolism, ischaemic stroke or
other peripheral embolism) among
patients with left-sided endocarditis
Major embolism/
total (%) OR (95% CI)
Adjusted OR
(95% CI)
Age
Per additional year 0.97 (0.95–0.99)a 0.97 (0.95–0.99)b
Sex
Male 39/151 (26) 1.00 NS
Female 21/74 (28) 1.14
Charlson score
0–1 28/74 (38) 1.00 NS
2–4 19/81 (23) 0.50 (0.25–1.01)
‡5 13/70 (18) 0.37 (0.17–0.80)
Prosthetic valve
No 42/169 (25) 1.00 NS
Yes 18/56 (32) 1.43 (0.74–2.77)
Pathogen
Streptococci 13/48 (27) 1.00 NS
Staphylococcus aureus 30/111 (27) 1.00 (0.47–2.14)
Coagulase-negative staphylococci 4/19 (21) 0.72 (0.20–2.51)
Enterococci 5/22 (23) 0.79 (0.24–2.58)
Other 6/17 (35) 1.47 (0.45–4.78)
Culture-negative 2/8 (25) 0.90 (0.16–5.02)
Aortic valve involved
No 33/151 (22) 1.00 NS
Yes 27/74 (36) 2.05 (1.12–3.78)b
Mitral valve involved
No 36/140 (25) 1.00 NS
Yes 24/85 (28) 1.14 (0.62–2.08)
Size of largest vegetation
No vegetation seen 20/124 (16) 1.00 1.00
<10 mm 16/45 (36) 2.87 (1.32–6.23)b 2.21 (0.96–5.11)
‡10 mm 24/56 (43) 3.90 (1.91–7.96)a 3.09 (1.44–6.65)b
Congestive heart failure, de novo
No 39/175 (22) 1.00 1.00
Yes 21/50 (42) 2.53 (0.30–4.91)b 2.56 (1.22–5.37)b
Perivalvular abscess
No 52/205 (25) 1.00
Yes 8/20 (40) 1.96 (0.76–5.06) NS
Atrioventricular block, de novo
No 44/197 (22) 1.00 1.00
Yes 16/28 (57) 4.64 (2.04–10.53)a 4.04 (1.54–10.65)b
Antiplatelet agents
None before, none after admission 36/131 (27) 1.00 NS
None before, started after admission 10/21 (48) 2.40 (0.94–6.13)
Chronic therapy before admission 14/73 (19) 0.63 (0.31–1.26)
Valve replacement
No 39/181 (21) 1.00 NS
Yes 21/44 (48) 3.32 (1.67–6.62)a
NS, not signiﬁcant.
ap £0.001.
bp <0.05.
CMI Pepin et al. Antiplatelet agents in infective endocarditis 197
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 193–199
potential confounding factors was collected and adjusted for in
a logistic regression analysis, it cannot be ruled out that there
might have been other unmeasured confounders. Second, this
was a single-centre study, and the sample size was limited
when the effect of antiplatelets was examined in some
subgroups, e.g. of patients with S. aureus IE. Among the latter,
the effect of chronic antiplatelet therapy was not statistically
signiﬁcant, but tended towards lower mortality as well. Third,
about half of the patients did not have vegetations, as detected
by echocardiography; this reﬂects the long time-span of the
study and the infrequent use of transoesophageal echocardio-
graphy in the earlier years. Finally, whether this beneﬁcial
effect of aspirin therapy could be replicated through an
intervention initiated only at the time of diagnosis, when
vegetations and valvular damage are already present, remains
uncertain. A trend for a decrease in mortality among patients
for whom therapy with antiplatelet drugs had been initiated
after admission was noted, with an effect (AOR) very similar
to that observed among patients receiving chronic antiplatelet
therapy. However, this was based on a small number of
patients (n = 23), with substantial variations in the interval
between diagnosis and initiation of therapy with an antiplatelet
drug, and in the duration of that therapy.
Only an adequately powered randomized controlled trial,
with mortality as the primary criterion of outcome, would
overcome all of these limitations. As IE is an uncommon dis-
ease, such a trial would require the participation of many
centres, would be very expensive and would be unlikely to
be sponsored by industry. A more feasible approach would
be an attempt to replicate the present ﬁndings within a lar-
ger cohort of patients with IE treated in multiple centres,
e.g. by exploiting the large database set up by the Interna-
tional Collaboration on Endocarditis [6].
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